Education
About Us
Working with TipRanks
Follow Us
Immucell Corp. (ICCC)
NASDAQ:ICCC
Earnings Data
Report Date
Aug 07, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
―Last Year’s EPS
-0.2Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 14, 2025
|% Change Since: 27.29%
|Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong sales growth, improved gross margins, and significant adjusted EBITDA performance, driven by increased production capacity and product line expansion. However, challenges remain with FDA licensing for Re-Tain and managing backlog, alongside potential sales variability due to seasonality.Company Guidance
During the recent ImmuCell Corporation conference call, the company provided several key financial metrics and insights for the first quarter of fiscal year 2025. ImmuCell reported a record quarterly product sales revenue of $8.1 million, marking an 11% increase from the same period in 2024. The company also achieved a gross margin of 42% for the quarter, up from 37% in the fourth quarter of 2024, although they aim to reach at least 45%. Adjusted EBITDA showed significant improvement, with $2.3 million for the first quarter, compared to just $458,000 in the first quarter of 2024. The company's cash balance increased to $4.6 million as of March 31, 2025. ImmuCell reduced its order backlog from $4.4 million at the end of 2024 to $4 million by the end of the first quarter of 2025, with further reductions to $3.4 million by early May 2025. The company completed investments to expand production capacity to over $30 million annually, which contributed to their recent growth and financial recovery.Record-Breaking Sales Growth
Product sales during the first quarter of 2025 increased by 11% or $810,000 over the first quarter of 2024, reaching a record $8.1 million. This surpassed the previous record set in the fourth quarter of 2024.
Gross Margin Improvement
The gross margin increased to 42% in Q1 2025, up from 37% in Q4 2024, indicating operational improvements and higher production efficiency.
Significant Adjusted EBITDA Growth
Adjusted EBITDA improved significantly to $2.3 million in Q1 2025, compared to $458,000 in Q1 2024.
Successful Production Capacity Expansion
ImmuCell's production capacity increased to over $30 million annually, supporting future growth and reducing backlog from $4.4 million to $3.4 million.
First Defense Product Line Expansion
Introduction of new product formats for First Defense, expanding its use and market appeal.
No Recent Contamination Events
No contamination events reported for over a year, indicating improved production processes.
ICCC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ICCC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 14, 2025 | $4.91 | $5.30 | +7.94% |
Feb 25, 2025 | $5.10 | $5.48 | +7.45% |
Nov 13, 2024 | $3.53 | $3.60 | +1.98% |
Aug 13, 2024 | $3.76 | $3.60 | -4.26% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Immucell Corp. (ICCC) report earnings?
Immucell Corp. (ICCC) is schdueled to report earning on Aug 07, 2025, TBA Not Confirmed.
What is Immucell Corp. (ICCC) earnings time?
Immucell Corp. (ICCC) earnings time is at Aug 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ICCC EPS forecast?
Currently, no data Available